Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbbVie

186.39
-3.4900-1.84%
Pre-market: 187.000.6100+0.33%08:58 EDT
Volume:6.73M
Turnover:1.26B
Market Cap:329.24B
PE:79.66
High:190.67
Open:190.21
Low:185.01
Close:189.88
Loading ...

LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million

Motley Fool
·
08 Jul

AbbVie’s (ABBV) Forecasts Lower Q2 EPS on R&D Costs

TIPRANKS
·
05 Jul

Iovance Biotherapeutics Appoints Matthew W. Rosinack as Interim Principal Financial Officer Following Departure of Jean-Marc Bellemin

Reuters
·
04 Jul

BRIEF-Abbvie Inc Reports $823 Million IPR&D And Milestones Expense For Q2 2025

Reuters
·
04 Jul

Abbvie Inc - Expense Impacts Q2 Gaap and Non-Gaap EPS by $0.42 - SEC Filing

THOMSON REUTERS
·
04 Jul

Abbvie Inc - Reports $823 Mln Ipr&D and Milestones Expense for Q2 2025 - SEC Filing

THOMSON REUTERS
·
04 Jul

AbbVie Inc. Lowers Forecasted 2025 Adjusted EPS to $11.67-$11.87 Due to $1.071 Billion Milestone Expense Impact

Reuters
·
04 Jul

AbbVie’s New Study on Targeted Therapies for Rheumatoid Arthritis: What Investors Need to Know

TIPRANKS
·
04 Jul

AbbVie’s Promising Phase 3 Study on Telisotuzumab Vedotin for NSCLC

TIPRANKS
·
04 Jul

AbbVie’s Pediatric Atopic Dermatitis Study: A Potential Game-Changer?

TIPRANKS
·
03 Jul

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
01 Jul

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires Live
·
01 Jul

Deals of the Day-Mergers and acquisitions

Reuters
·
30 Jun

Dow Jones Top Company Headlines at 9 AM ET: Home Depot to Buy GMS for $4.3 Billion | AbbVie ...

Dow Jones
·
30 Jun

AbbVie to Acquire Capstan Therapeutics for up to $2.1 Billion

MT Newswires Live
·
30 Jun

AbbVie to Acquire Capstan Therapeutics, Expanding Commitment to Innovative Immunology Care

Reuters
·
30 Jun

Abbvie Inc - to Pay up to $2.1 Bln in Cash for Capstan

THOMSON REUTERS
·
30 Jun

Abbvie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

THOMSON REUTERS
·
30 Jun

FDA Accepts Allergan Aesthetics' Premarket Approval Application for SKINVIVE by JUVÉDERM® to Improve Neck Appearance

Reuters
·
30 Jun

U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by JuvÉDerm® for the Improvement of Neck Appearance

THOMSON REUTERS
·
30 Jun